Consensus Tempus AI, Inc. Mexican S.E.

Stocks

TEM *

US88023B1035

Biotechnology & Medical Research

End-of-day quote Mexican S.E. 2026-08-28			5-day change	1st Jan Change
1,089.00 ^MXN	-9.25%		-11.46%	+2.64%

08-24	Tempus AI Receives FDA Clearance For Tempus ECG-PH AI Product Intended To Detect Signs Of Pulmonary Hypertension From Standard ECGs	CI
08-24	Tempus AI Gets FDA Clearance for AI-Enabled Pulmonary Hypertension Detector	MT

Evolution of the Average Target: Tempus AI, Inc.

Evolution of the Target Price: Tempus AI, Inc.

Changes in Analyst Recommendations: Tempus AI, Inc.

8.YO3Hd3VM6oQHo627JAF_F8lkhZLQcTsNnDBNKR2iJ2k.JcDyGDg627xo7vXrQ04WY7sRxOOTCwln1kgYcFPEQSUS3akFJxaG40nR6A~35116a4f7e4723887974ba033d6c18dc

Analysts' recommendations: Tempus AI, Inc.

05:18am	Analyst recommendations: Duolingo, Robinhood, Adobe, CrowdStrike, Salesforce…
07-20	Personalis Acquisition Price Warranted by Growth Prospects, Needham Says	MT
07-20	Tempus AI to Buy Cancer Test Maker Personalis; Needham Says Deal Premium Well Above Peers	MT
07-20	Top Midday Decliners	MT
04-13	TD Cowen Upgrades Tempus AI to Buy From Hold, Adjusts Price Target to $65 From $70	MT
04-13	Jefferies Initiates Tempus AI at Underperform With $35 Price Target	MT
02-25	Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead…
02-19	Mizuho Securities Initiates Coverage on Tempus AI With Outperform Rating, $100 Price Target	MT
02-17	Baird Initiates Tempus AI at Outperform With $59 Price Target	MT
12-02	Morgan Stanley Raises Price Target on Tempus AI to $85 From $80, Keeps Overweight Rating	MT
11-11	Analyst recommendations: Coreweave, Duolingo, Lyft, Qualcomm, Tempus…
25-10-22	Analyst recommendations: 3M Company, Gartner, Halliburton, GM, Warner Bros Discovery…
25-10-21	Tempus AI Shares Lower After TD Cowen Downgrade	MT
25-10-21	TD Cowen Downgrades Tempus AI to Hold From Buy, Adjusts Price Target to $88 From $72	MT
25-10-20	Canaccord Genuity Initiates Coverage on Tempus AI With Buy Rating, $110 Price Target	MT
25-09-02	HC Wainwright Initiates Tempus AI at Buy With $90 Price Target	MT
25-08-05	Healthcare firm Personalis' Q2 revenue misses estimates	RE
25-04-21	BTIG Initiates Tempus AI at Buy With $60 Price Target	MT
25-02-26	Wolfe Research Downgrades Tempus AI to Peer Perform From Outperform	MT
25-02-25	Tempus AI Shares Fall After Downgrade from JPMorgan	MT
25-02-25	JPMorgan Downgrades Tempus AI to Neutral From Overweight, Adjusts Price Target to $55 From $50	MT
25-02-12	William Blair Downgrades Tempus AI to Market Perform From Outperform	MT
25-01-07	President Capital Initiates Tempus AI at Buy With $52 Price Target	MT
24-12-13	Wolfe Initiates Tempus AI at Outperform With $60 Price Target	MT
24-12-09	Guggenheim Initiates Tempus AI at Buy With $74 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LONZA GROUP AG					+18.13%
	REVOLUTION MEDICINES, INC.					+21.02%
	IQVIA HOLDINGS INC.					+5.35%
	BEONE MEDICINES AG					+20.18%
	CELLTRION, INC.					+40.83%
	MEDPACE HOLDINGS, INC.					-2.05%
	ASCENDIS PHARMA A/S					+19.48%
	EUROFINS SCIENTIFIC SE					-0.02%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					-2.51%
	Average					+13.38%
	Weighted average by Cap.					+16.49%